During the ASH meeting, there were two presentation about the combination between azacitidine and syros-1425. It’s a new drug with a new target. 30% of acute myeloid leukemia and myelodysplastic syndrome have overexpression of RARA and the syros is a targeted therapy in this specific subgroup.
So, the first presentation was presented by De Botton, et al, in first line acute myeloid leukemia, not eligible for intensive chemo...
During the ASH meeting, there were two presentation about the combination between azacitidine and syros-1425. It’s a new drug with a new target. 30% of acute myeloid leukemia and myelodysplastic syndrome have overexpression of RARA and the syros is a targeted therapy in this specific subgroup.
So, the first presentation was presented by De Botton, et al, in first line acute myeloid leukemia, not eligible for intensive chemo. And, the overall response rate was really high with 67% of overall response rate, including 61% of complete remission, with a median overall survival at 8.4 months. A second presentation in relapse refractory acute myeloid leukemia was presented by Stein, et al, and the overall response rate was 19%, including a 10% of complete remission with a median overall survival at 5.9 months. This subgroup of patient is independent of molecular subtype. So, this new drug could be interesting in all subtype of acute myeloid leukemia, in patients, of course, with RARA positive.